Latest News

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial




NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

Source link

Related posts

AI-Powered Metabolic Health Program from January.ai Accurately Predicts Individualized Glycemic Response in People with Type 2 Diabetes

Newsemia

US craze for DNA 'heritage' tests may bolster racism, critics warn

Newsemia

How sickled red blood cells stick to blood vessels

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World